Burnett, W.J.; Burnett, D.M.; Parkman, G.; Ramstead, A.; Contreras, N.; Gravley, W.; Holmen, S.L.; Williams, M.A.; VanBrocklin, M.W.
Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers 2021, 13, 4462.
https://doi.org/10.3390/cancers13174462
AMA Style
Burnett WJ, Burnett DM, Parkman G, Ramstead A, Contreras N, Gravley W, Holmen SL, Williams MA, VanBrocklin MW.
Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers. 2021; 13(17):4462.
https://doi.org/10.3390/cancers13174462
Chicago/Turabian Style
Burnett, William J., David M. Burnett, Gennie Parkman, Andrew Ramstead, Nico Contreras, William Gravley, Sheri L. Holmen, Matthew A. Williams, and Matthew W. VanBrocklin.
2021. "Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy" Cancers 13, no. 17: 4462.
https://doi.org/10.3390/cancers13174462
APA Style
Burnett, W. J., Burnett, D. M., Parkman, G., Ramstead, A., Contreras, N., Gravley, W., Holmen, S. L., Williams, M. A., & VanBrocklin, M. W.
(2021). Prior Exposure to Coxsackievirus A21 Does Not Mitigate Oncolytic Therapeutic Efficacy. Cancers, 13(17), 4462.
https://doi.org/10.3390/cancers13174462